Biotech · Public company · Redwood City, CA, US
Revolution Medicines, Inc.
Ticker RVMD · SEC CIK 0001628171
Track this companyFree. Adds Revolution Medicines, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials2519 recruiting or active
Pipeline programs45From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline45
- 5-FluorouracilPhase 3 · Pancreatic CancerClinicalTrials.gov · fetched Nov 12, 2026
- daraxonrasibPhase 3 · Pancreatic CancerClinicalTrials.gov · fetched Nov 12, 2026
- daraxonrasibPhase 3 · NSCLC (Non-small Cell Lung Cancer)ClinicalTrials.gov · fetched Nov 12, 2026
- docetaxelPhase 3 · NSCLC (Non-small Cell Lung Cancer)ClinicalTrials.gov · fetched Nov 12, 2026
- gemcitabinePhase 3 · Pancreatic CancerClinicalTrials.gov · fetched Nov 12, 2026
- IrinotecanPhase 3 · Pancreatic CancerClinicalTrials.gov · fetched Nov 12, 2026
- Leucovorin (Calcium Folinate)Phase 3 · Pancreatic CancerClinicalTrials.gov · fetched Nov 12, 2026
- Liposomal irinotecanPhase 3 · Pancreatic CancerClinicalTrials.gov · fetched Nov 12, 2026
- nab-paclitaxelPhase 3 · Pancreatic CancerClinicalTrials.gov · fetched Nov 12, 2026
- OxaliplatinPhase 3 · Pancreatic CancerClinicalTrials.gov · fetched Nov 12, 2026
- pembrolizumabPhase 3 · NSCLCClinicalTrials.gov · fetched Nov 12, 2026
- pemetrexed + cisplatin /carboplatinPhase 3 · NSCLCClinicalTrials.gov · fetched Nov 12, 2026
- RMC-6236Phase 3 · Pancreatic CancerClinicalTrials.gov · fetched Nov 12, 2026
- zoldonrasibPhase 3 · NSCLCClinicalTrials.gov · fetched Nov 12, 2026
- ZoldonrasibPhase 3 · Pancreatic CancerClinicalTrials.gov · fetched Nov 12, 2026
- bevacizumabPhase 2 · Colorectal CancerClinicalTrials.gov · fetched Nov 12, 2026
- CarboplatinPhase 2 · Non-Small Cell Lung Cancer, NSCLCClinicalTrials.gov · fetched Nov 12, 2026
- Carboplatin/Cisplatin + Pemetrexed (Dose Expansion Only)Phase 2 · Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- cetuximabPhase 2 · Colorectal CancerClinicalTrials.gov · fetched Nov 12, 2026
- cetuximab (Cohort C2 Only)Phase 2 · Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- CisplatinPhase 2 · Non-Small Cell Lung Cancer, NSCLCClinicalTrials.gov · fetched Nov 12, 2026
- CobimetinibPhase 2 · Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- DaraxonrasibPhase 2 · Non-Small Cell Lung Cancer (NSCLC)ClinicalTrials.gov · fetched Nov 12, 2026
- DaraxonrasibPhase 2 · Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- Drug: OsimertinibPhase 2 · Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- ElironrasibPhase 2 · Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- ElironrasibPhase 2 · Non-Small Cell Lung Cancer (NSCLC)ClinicalTrials.gov · fetched Nov 12, 2026
- gemcitabinePhase 2 · Colorectal CancerClinicalTrials.gov · fetched Nov 12, 2026
- IvonescimabPhase 2 · Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- mFOLFIRINOX regimenPhase 2 · Colorectal CancerClinicalTrials.gov · fetched Nov 12, 2026
- mFOLFOX6 regimenPhase 2 · Colorectal CancerClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 2 · Non-Small Cell Lung Cancer, NSCLCClinicalTrials.gov · fetched Nov 12, 2026
- PemetrexedPhase 2 · Non-Small Cell Lung Cancer, NSCLCClinicalTrials.gov · fetched Nov 12, 2026
- RMC-4630Phase 2 · Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- RMC-4630Phase 2 · Non-Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- RMC-6236Phase 2 · Colorectal CancerClinicalTrials.gov · fetched Nov 12, 2026
- RMC-6236Phase 2 · Non-Small Cell Lung Cancer, NSCLCClinicalTrials.gov · fetched Nov 12, 2026
- RMC-6291Phase 2 · Non-Small Cell Lung Cancer, NSCLCClinicalTrials.gov · fetched Nov 12, 2026
- SotorasibPhase 2 · Non-Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- ZoldonrasibPhase 2 · Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- cetuximabPhase 1 · Non-small Cell Lung Cancer (NSCLC)ClinicalTrials.gov · fetched Nov 12, 2026
- RMC-5127Phase 1 · Non-small Cell Lung Cancer (NSCLC)ClinicalTrials.gov · fetched Nov 12, 2026
- RMC-5552Phase 1 · Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- RMC-9805Phase 1 · Non-small Cell Lung Cancer (NSCLC)ClinicalTrials.gov · fetched Nov 12, 2026
- daraxonrasibPDACClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials25
- Daraxonrasib in Resectable PDACPHASE1 · NOT_YET_RECRUITING · started Apr 13, 2027ClinicalTrials.gov NCT07898813 · fetched Nov 12, 2026
- Phase 2 Study of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract CancerPHASE2 · NOT_YET_RECRUITING · started Nov 1, 2026ClinicalTrials.gov NCT07793253 · fetched Nov 12, 2026
- First in Human Study of SNV1521 With a RAS Inhibitor for People With Advanced Pancreatic CancerPHASE1 · RECRUITING · started Sep 1, 2026ClinicalTrials.gov NCT07756281 · fetched Nov 12, 2026
- Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic AdenocarcinomaPHASE3 · RECRUITING · started Aug 28, 2026ClinicalTrials.gov NCT07805954 · fetched Nov 12, 2026
- Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLCPHASE3 · RECRUITING · started Aug 14, 2026ClinicalTrials.gov NCT07777822 · fetched Nov 12, 2026
- Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )PHASE3 · RECRUITING · started May 22, 2026ClinicalTrials.gov NCT07621718 · fetched Nov 12, 2026
- Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic AdenocarcinomaPHASE3 · RECRUITING · started Mar 9, 2026ClinicalTrials.gov NCT07491445 · fetched Nov 12, 2026
- Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid TumorsPHASE1_PHASE2 · RECRUITING · started Jan 30, 2026ClinicalTrials.gov NCT07397338 · fetched Nov 12, 2026
- Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid TumorsPHASE1 · RECRUITING · started Jan 8, 2026ClinicalTrials.gov NCT07349537 · fetched Nov 12, 2026
- Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)PHASE3 · RECRUITING · started Dec 15, 2025ClinicalTrials.gov NCT07252232 · fetched Nov 12, 2026
- Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC PatientsPHASE1_PHASE2 · RECRUITING · started May 31, 2025ClinicalTrials.gov NCT06922591 · fetched Nov 12, 2026
- Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)PHASE3 · RECRUITING · started May 6, 2025ClinicalTrials.gov NCT06881784 · fetched Nov 12, 2026
- Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)PHASE3 · ACTIVE_NOT_RECRUITING · started Oct 16, 2024ClinicalTrials.gov NCT06625320 · fetched Nov 12, 2026
- Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid TumorsPHASE1_PHASE2 · RECRUITING · started May 24, 2024ClinicalTrials.gov NCT06445062 · fetched Nov 12, 2026
- Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLCPHASE1_PHASE2 · RECRUITING · started Jan 18, 2024ClinicalTrials.gov NCT06162221 · fetched Nov 12, 2026
- Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid TumorsPHASE1_PHASE2 · RECRUITING · started Nov 14, 2023ClinicalTrials.gov NCT06128551 · fetched Nov 12, 2026
- Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid TumorsPHASE1 · RECRUITING · started Sep 7, 2023ClinicalTrials.gov NCT06040541 · fetched Nov 12, 2026
- RMC-5552 Monotherapy in Adult Subjects With Recurrent GlioblastomaPHASE1 · TERMINATED · started Apr 3, 2023ClinicalTrials.gov NCT05557292 · fetched Nov 12, 2026
- Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid TumorsPHASE1 · ACTIVE_NOT_RECRUITING · started Sep 19, 2022ClinicalTrials.gov NCT05462717 · fetched Nov 12, 2026
- Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RASPHASE1_PHASE2 · RECRUITING · started May 31, 2022ClinicalTrials.gov NCT05379985 · fetched Nov 12, 2026
- Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard TherapiesPHASE2 · COMPLETED · started Dec 30, 2021ClinicalTrials.gov NCT05054725 · fetched Nov 12, 2026
- Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid TumorsPHASE1 · COMPLETED · started Apr 7, 2021ClinicalTrials.gov NCT04774952 · fetched Nov 12, 2026
- Safety and Efficacy Study of Vociprotafib (SAR442720) in Combination With Other Agents in Advanced MalignanciesPHASE1_PHASE2 · TERMINATED · started Jun 9, 2020ClinicalTrials.gov NCT04418661 · fetched Nov 12, 2026
- Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLCPHASE1_PHASE2 · COMPLETED · started Jul 2, 2019ClinicalTrials.gov NCT03989115 · fetched Nov 12, 2026
- Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic AdenocarcinomaAPPROVED_FOR_MARKETINGClinicalTrials.gov NCT07573215 · fetched Nov 12, 2026
SEC filings12
- 10-Q · 10-QSEC EDGAR · filed Nov 4, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Nov 4, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Oct 13, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Sep 1, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 26, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Aug 5, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 5, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 22, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 6, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 6, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Apr 17, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Apr 16, 2026 · fetched Nov 12, 2026